Fundraising Fox

Daniel L. Vasella, M.D.

Investor

Advisor at Time BioVentures

Basel, Basel, Switzerland

About

Daniel Vasella, M.D., is Chairman of the Board of Numab Therapeutics AG, having joined the board in 2019 and become Chairman in 2020. He previously served as Chairman of Novartis AG from 1999 to 2013 and as its CEO from 1996 to 2010, and earlier held CEO and senior development and marketing roles at Sandoz Pharma. He earned an M.D. from the University of Bern in 1980 and completed studies at Harvard Business School.

Invests in

Biotech

Experience

  1. POP DüsseldorfFaculty Membercurrent2016 — present
  2. Numab Therapeutics AGChairman Of The Board2020 — 2023Schlieren, Zurich, Switzerland
  3. NovartisChairman1999 — 2013
  4. Novartis AGCEO1996 — 2010

Education

  1. University of Bern and University of FribourgDoctor of Medicine (M.D.)1973 — 1979

Skills & more

Pharmaceutical Industry55Clinical Development29Oncology13Clinical Trials9Biotechnology15Pharmaceutical Sales16Drug Development29Lifesciences8Regulatory Affairs8Drug Discovery13Sales Effectiveness12Technology Transfer7
+4 moreMarket AccessCardiologyDiabetesLife Sciences

Languages English · French · German

From Daniel's professional profile.

Investments

Board seats

American Express CompanyNumab Therapeutics AGPepsiCoSciClone Pharmaceuticals

Per the firm's website.

Colleagues at Time BioVentures

Frequently asked questions

Where does Daniel L. Vasella, M.D. work?
Daniel L. Vasella, M.D. is Advisor at Time BioVentures.
What does Daniel L. Vasella, M.D. invest in?
Daniel L. Vasella, M.D. invests in Biotech.

Shared employers